Want to see IN:LASA full AI Analyst Report?
LASA Stock Chart & Stats
₹11.33
-₹1.79(-6.22%)
At close: 4:00 PM EST
₹11.33
-₹1.79(-6.22%)
Day’s Range― - ―
52-Week Range₹5.65 - ₹14.14
Previous CloseN/A
Volume56.48K
Average Volume (3M)39.13K
Market Cap
₹375.76M
Enterprise Value₹471.28M
Total Cash (Recent Filing)₹6.96M
Total Debt (Recent Filing)₹73.38M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.73
Shares Outstanding50,101,240
10 Day Avg. Volume9,122
30 Day Avg. Volume39,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)1.13
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageSustained low debt-to-equity provides durable financial flexibility: it lowers fixed interest obligations, preserves borrowing capacity for working capital or capex, and gives management room to restructure operations or fund recovery without immediate dilution or distress financing.
B2B API Manufacturing ModelA B2B API supplier benefits from repeat purchasing, longer customer relationships and quality/regulatory barriers to entry. These structural traits support stable long-term demand from formulators and finished-dosage manufacturers if product quality and compliance are maintained.
Product DiversificationServing multiple therapeutic categories reduces concentration risk tied to any single molecule or therapy cycle. This diversification supports steadier addressable demand, improving the likelihood of revenue recovery as some product lines can offset weakness in others over months to years.
Bears Say
Severe Revenue DeclineA near three-quarter revenue collapse is a structural red flag: it can reflect lost contracts, market-share erosion or product obsolescence. Sustained low scale undermines margins, reduces bargaining power with suppliers, and makes fixed-cost absorption and recovery materially harder.
Deep Negative MarginsNegative gross margin indicates costs exceed sales at the production level, pointing to structural pricing pressure, cost overruns, or large write-downs. Such deficits destroy equity, limit reinvestment, and are difficult to correct quickly without meaningful operational or commercial restructuring.
Weak And Inconsistent Cash FlowRecurrent negative operating cash flow forces reliance on external funding and raises refinancing or dilution risk. Inability to self-fund working capital and compliance investments impairs long-term competitiveness in a regulated API market and constrains options for recovery.
Lasa Supergenerics Ltd. News
LASA FAQ
What was Lasa Supergenerics Ltd.’s price range in the past 12 months?
Lasa Supergenerics Ltd. lowest stock price was ₹5.65 and its highest was ₹14.14 in the past 12 months.
What is Lasa Supergenerics Ltd.’s market cap?
Lasa Supergenerics Ltd.’s market cap is ₹375.76M.
When is Lasa Supergenerics Ltd.’s upcoming earnings report date?
Lasa Supergenerics Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were Lasa Supergenerics Ltd.’s earnings last quarter?
Lasa Supergenerics Ltd. released its earnings results on May 29, 2026. The company reported -₹0.83 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.83.
Is Lasa Supergenerics Ltd. overvalued?
According to Wall Street analysts Lasa Supergenerics Ltd.’s price is currently Overvalued.
Does Lasa Supergenerics Ltd. pay dividends?
Lasa Supergenerics Ltd. pays a Annually dividend of ₹0.25 which represents an annual dividend yield of N/A. See more information on Lasa Supergenerics Ltd. dividends here
What is Lasa Supergenerics Ltd.’s EPS estimate?
Lasa Supergenerics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lasa Supergenerics Ltd. have?
Lasa Supergenerics Ltd. has 50,101,240 shares outstanding.
What happened to Lasa Supergenerics Ltd.’s price movement after its last earnings report?
Lasa Supergenerics Ltd. reported an EPS of -₹0.83 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.217%.
Which hedge fund is a major shareholder of Lasa Supergenerics Ltd.?
Currently, no hedge funds are holding shares in IN:LASA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lasa Supergenerics Ltd.
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Mangalam Drugs & Organics Ltd.
―
Par Drugs and Chemicals Limited
―
Vivimed Labs Limited
―